The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|October 21, 2020
Vetter Moves into New Headquarters and Continues Long-Term Investment
Author(s)Pharmaceutical Technology Editors
Vetter has moved into new headquarters located in Ravensburg, Germany, and plans to continue its long-term investment for corporate development.
Advertisement
Global contract development and manufacturing organization (CDMO), Vetter, has announced its move into new headquarters located in Ravensburg, Germany, and plans to continue long-term investment for corporate development.
According to an Oct. 21, 2020 press release, the new Ravensburg Vetter Kammerbruehl has been opened in response to the company’s growing headcount and changing circumstances. The new headquarters is designed for approximately 1000 employees, while the former headquarters has been modified to be used as a training center and house the Vetter Academy.
Additionally, Vetter has invested in other sites, such as a new combination building for manual visual inspection and secondary packaging at its Ravensburg Vetter Sued site, and a cleanroom for prefilled syringe manufacturing at the Schuetzenstrasse site, which is expected to be operational in 2021.
“We are relying on sustainable and future-oriented activities with the focus on our customers and their patients,” said Peter Soelkner, managing director, Vetter, in the press release.“Part of our 360-degree approach includes investments in the expansion of our development capacities. We have observed a steady increase in demand from our customers as well as ever-more complex requirements for modern compounds.”
Further expansion is also planned by the company in the area of quality control. After Vetter’s implementation of a machine for automated visual inspection, the company has revealed plans to purchase three additional units for the Center for Visual Inspection and Logistics.
“We want to provide sufficient resources for the important step of final quality control and, at the same time, create greater flexibility,” added Thomas Otto, managing director, Vetter, in the press release. “These actions will even better enable us to offer our customers either manual or automatic visual inspection depending on individual batch sizes and special characteristics of their products.”
Source:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5